The Technical Analyst
XORTX Therapeutics Inc. [XRTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
XORTX Therapeutics Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
13.13% $2.93
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 52.71 mill |
| EPS: | -0.410 |
| P/E: | -7.15 |
| Earnings Date: | Aug 10, 2023 |
| SharesOutstanding: | 17.99 mill |
| Avg Daily Volume: | 0.0501 mill |
| RATING 2024-04-26 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.15 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.22x |
| Company: PE -7.15 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.575 (-80.36%) $-2.35 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.39 - 3.48 ( +/- 18.60%) |
| ATR Model: 14 days |
Forecast:
16:00 - $2.93
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.93
Forecast 2: 16:00 - $2.93
Forecast 3: 16:00 - $2.93
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.93 (13.13% ) |
| Volume | 0.0250 mill |
| Avg. Vol. | 0.0501 mill |
| % of Avg. Vol | 49.98 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For XRTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
XRTX
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Latest Press Releases
2024-04-22 07:00:00 - Press Release
Xortx Announces Publication Of Key Research In Adpkd
Calgary, alberta, april 22, 2024 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anua wkn: a3unz), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a research paper titled “raising serum uric acid with a uricase inhibitor worsens pkd in rat and mouse models" has been accepted for publication in the peer-reviewed american journal of physiology-renal physiology and published online april 19, 2024.
2024-04-08 07:30:00 - Press Release
Xortx Welcomes New Member To The Board Of Directors
Calgary, alberta, april 08, 2024 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anua wkn: a3unz), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes abigail jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its board of directors.
2024-03-27 05:00:00 - Press Release
Xortx Announces New Clinical advisory Board Member
Calgary, alberta, march 27, 2024 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anua wkn: a3unz), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease (“adpkd”), is pleased to announce that dr. ronald perrone has joined the company's clinical advisory board.
2024-03-19 05:00:00 - Press Release
Xortx Highlights Achievements Of 2023 And Preparation For Registration Clinical Trial
Calgary, alberta, march 19, 2024 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anua wkn: a3unz), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide a summary of company's achievements in 2023 and objectives planned for 2024.
2024-03-04 07:00:00 - Press Release
Xortx Finalizes $2.7 Million Prospectus Supplement And Concurrent Private Placement For The Offering Of Units
Not for distribution to united states news wire servicesor for dissemination in the united states calgary, alberta, march 04, 2024 (globe newswire) -- xortx therapeutics inc. (“xortx” or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a second tranche closing (the “second tranche closing”) of gross proceeds of cad $224,850 under previously announced offering, including cad $99,000 in a concurrent private placement of the company in connection with international subscribers. the company completed the second tranche closing under the same terms of the previously announced first tranche closing on february 15, 2024 (the “first tranche closing”).
Latest News
2023-10-25 17:00:00 - GlobeNewsWire
XORTX Announces Date for Rescheduled Special Meeting of Shareholders
CALGARY, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its earlier press release, the special meeting of shareholders has been rescheduled to 10:00 a.m. (Calgary time) on Friday, October 27, 2023 (the “Meeting”).
2023-10-23 09:10:16 - InvestorPlace
Why Is Xortx Therapeutics (XRTX) Stock Down 27% Today?
Xortx Therapeutics (NASDAQ: XRTX ) stock is sliding lower on Monday as the pharmaceutical company's shares come off of a recent rally. Shares of XRTX stock closed out normal trading hours on Friday up 100.6%.
2023-10-20 08:42:28 - InvestorPlace
Why Is Xortx Therapeutics (XRTX) Stock Up 110% Today?
Xortx Therapeutics (NASDAQ: XRTX ) stock is climbing higher on Friday despite a lack of news from the pharmaceutical company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) from Xortx Therapeutics that would cause today's rally.
2023-01-19 11:37:38 - InvestorPlace
Why Is Xortx Therapeutics (XRTX) Stock Up 30% Today?
There's great news circulating about Xortx Therapeutics (NASDAQ: XRTX ) today. In a clinical study, XORLO, Xortx's orally administered brand of oxypurinol, demonstrated a “substantial increase” in bioavailability.
2022-11-03 10:15:00 - GlobeNewsWire
XORTX Announces Participation at Upcoming Investor Conferences
CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that Dr. Allen Davidoff, President and CEO, is scheduled to participate in the following upcoming investor conferences:
2022-07-13 08:39:02 - Benzinga
Why Are XORTX Therapeutics Shares Skyrocketing Today?
XORTX Therapeutics Inc (NASDAQ: XRTX) has announced topline results from Part 1 of the three-part Pharmacokinetics Bridging Study – XRX-OXY-101. The data showed a substantial increase in oral bioavailability of two versions of XORTX's proprietary oxypurinol formulation.
2022-07-13 08:11:44 - Pulse2
XORTX Therapeutics (XRTX) Stock: Why It Skyrocketed Over 90% Today
The stock price of XORTX Therapeutics Inc (NASDAQ: XRTX) skyrocketed by over 90% pre-market today. This is why.
2022-06-13 08:55:00 - GlobeNewsWire
XORTX to Present at BIO International Convention 2022
CALGARY, Alberta, June 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the BIO International Convention 2022, being held June 13th through 16th, 2022. Dr. Allen Davidoff, XORTX's CEO, will present an overview on the Company, including the Company's progress to date and planned future regulatory and clinical activities.
2022-03-23 15:45:04 - Benzinga
Here's Why XORTX Therapeutics Shares Are Rising
XORTX Therapeutics (NASDAQ: XRTX) shares are trading higher by 54.6% at $1.87 after the company announced the submission of a Patent Cooperation Treaty patent application seeking international patent protection for the patent entitled "Compositions and Methods for Enhancing Anti-Vi.
2021-10-15 17:38:00 - GlobeNewsWire
XORTX Therapeutics Announces Closing of US$12 Million Public Offering
CALGARY, Alberta, Oct. 15, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, today announced the closing of an underwritten public offering of 2,906,000 units ("Units"), with each Unit consisting of one common share, no par value, and one warrant ("Warrant") to purchase one common share at a public offering price of US$4.13 per Unit, for aggregate gross proceeds of approximately US$12 million, prior to deducting underwriting discounts and other offering expenses (the “Offering”). The common shares and warrants contained in the Units are immediately separable upon issuance...